Nuvectis Pharma Inc (NVCT) Stock Price, Quote & News

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 614 3150

Website: www.nuvectis.com

Address:

1 Bridge Plaza, Suite 275, Fort Lee, United States

BioTrade2 Jul. 28 at 5:46 PM

$NVCT “No one sits on good data”

1 · Reply

WallStWireAds Jul. 27 at 8:41 PM

$NVCT NXP900: The Breakthrough Drug That Could Transform Nuvectis Pharma Into a Multi-Billion Dollar Biotech Giant https://venture-block.com/nxp900-the-breakthrough-drug-that-could-transform-nuvectis-pharma-into-a-multi-billion-dollar-biotech-giant/

0 · Reply

buyandsold Jul. 26 at 11:16 PM

$NVCT what does it pop to on NXP800?

1 · Reply

BioSensai Jul. 24 at 7:03 PM

$NVCT yesterday 1.5mm shares were traded as single block. Who was the buyer?

1 · Reply

ZR92x Jul. 24 at 6:55 PM

$NVCT Final comments - NXP800 sentiment is low, but if it surprises to the upside, I think it could lead to a dramatic change in the sentiment for this entire company even with NXP800 having a much lower TAM than NXP900. NXP900 is the main prize, but I am hopeful for good NXP800 data in the next few weeks. GLTA

1 · Reply

BioSensai Jul. 24 at 6:40 PM

$NVCT @cupcakes4jesus is fairly certain this big volume is from ATM usage. My understanding is with issuing shares ATM it takes buyers to do that otherwise price drops as it is dilution with no buying. Seems 1.5mm shares is A LOT and too much at once for a small daily volume of less than 100k shares.. A direct offering to a buyer makes more sense. thoughts?

2 · Reply

ZR92x Jul. 24 at 6:17 PM

$NVCT continuing from my comments below - I have been primarily in this for NXP900 data but dont sleep on NXP800 at all just because they didn’t talk about it much at the HCW conference

0 · Reply

ZR92x Jul. 24 at 6:09 PM

$NVCT i think Charles or someone keeps buying more - another big batch of $12 million or so yesterday. Are they buying for NXP800 or NXP900 or both? I am hoping for a nice surprise on NXP800 soon. If it’s good, I hope that Wall Street values it beyond just the ARID1a ovarian indication and into endometrial and possibly others with the ARID1a mutation. could be a few billion+ in TAM with read-through into these other indications. combined with NXP900 this could be a monster… I am willing to keep waiting. long time holder and lurker here

0 · Reply

cupcakes4jesus Jul. 23 at 8:13 PM

$NVCT more like tapping the ATM for 1.5m shares. Not a good sign given its open label data and they can see the data. Very odd they would tap the ATM so aggressively days before a crucial readout. Very sus to say the least.

0 · Reply

BioSensai Jul. 23 at 7:30 PM

$NVCT big things imminent!

1 · Reply

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 2 months ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 4:25 PM EDT - 3 months ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Mar 14, 2025, 8:00 AM EDT - 4 months ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Feb 7, 2025, 8:30 AM EST - 6 months ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 6, 2025, 2:00 PM EST - 6 months ago

Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback

Feb 5, 2025, 9:01 AM EST - 6 months ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 6 months ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nov 14, 2024, 2:23 PM EST - 9 months ago

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nov 5, 2024, 7:00 AM EST - 9 months ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 28, 2024, 8:21 AM EDT - 9 months ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Aug 29, 2024, 8:00 AM EDT - 11 months ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 6, 2024, 8:28 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

May 16, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 14, 2024, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 5, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Feb 9, 2024, 8:32 AM EST - 1 year ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Jan 3, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Sep 25, 2023, 7:30 PM EDT - 1 year ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Aug 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 10:14 AM EDT - 2 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 10, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Dec 1, 2022, 8:00 AM EST - 2 years ago

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nov 8, 2022, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

Oct 18, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 3, 2022, 4:30 PM EDT - 3 years ago

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

Sep 28, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

Sep 13, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

Sep 7, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

Aug 5, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

Aug 1, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement

Jun 21, 2022, 8:15 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of IND for NXP800

Jun 13, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

BioTrade2 Jul. 28 at 5:46 PM

$NVCT “No one sits on good data”

1 · Reply

WallStWireAds Jul. 27 at 8:41 PM

0 · Reply

buyandsold Jul. 26 at 11:16 PM

$NVCT what does it pop to on NXP800?

1 · Reply

BioSensai Jul. 24 at 7:03 PM

$NVCT yesterday 1.5mm shares were traded as single block. Who was the buyer?

1 · Reply

ZR92x Jul. 24 at 6:55 PM

1 · Reply

BioSensai Jul. 24 at 6:40 PM

2 · Reply

ZR92x Jul. 24 at 6:17 PM

$NVCT continuing from my comments below - I have been primarily in this for NXP900 data but dont sleep on NXP800 at all just because they didn’t talk about it much at the HCW conference

0 · Reply

ZR92x Jul. 24 at 6:09 PM

0 · Reply

cupcakes4jesus Jul. 23 at 8:13 PM

0 · Reply

BioSensai Jul. 23 at 7:30 PM

$NVCT big things imminent!

1 · Reply

BioSensai Jul. 23 at 7:07 PM

$NVCT I smell a direct offering of 1.5mm share pr soon. It seems the only way big money is able to load up

0 · Reply

F4651110 Jul. 23 at 6:55 PM

$NVCT signs could possibly indicate news tomorrow. Company usually announce news on Thursdays pre-market

0 · Reply

BioSensai Jul. 23 at 6:49 PM

$NVCT Something big happened today with a 1.5mm share buy a bit over $8. We will hear something within the next 24 hours

2 · Reply

essiepaul Jul. 23 at 5:13 PM

$NVCT more games by short sellers? The bs never ends in the den of thieves

1 · Reply

BioTrade2 Jul. 23 at 2:07 PM

$NVCT sitting and looking at ABVX

1 · Reply

BioSensai Jul. 22 at 4:03 PM

$NVCT Data imminent. AH today to Thursday

0 · Reply

BioSensai Jul. 21 at 4:24 PM

$NVCT data this week friends

1 · Reply

UNLV Jul. 21 at 3:15 PM

$NVCT FDA fast track process NXP800 comes with lower bar for approval. Trial needs stable disease or partial response/tumor shrinkage with limited toxicity. CEO referenced stable disease and tumor shrinkage around 50mg intermittent dosing. Seems 75mg intermittent will meet efficacy standards, side effects a ? answered by recent insider buys imo

0 · Reply

cupcakes4jesus Jul. 20 at 3:09 AM

$NVCT I take all of what I said back about @BioSensai … we’re back to being good pals

0 · Reply

cupcakes4jesus Jul. 20 at 1:09 AM

$NVCT live picture of @BioSensai

0 · Reply

cupcakes4jesus Jul. 20 at 1:02 AM

$NVCT @BioSensai aka Nicholas Meyer is probably the biggest idiot I have ever come across on any platform I’ve ever been on. He belongs on TikTok twerking and showing off his body. Not on X or StockTwits. The guy changes from bear to bull to bear back to bull over night, and is a literal reet. He repeats the same 3 sentences 50+ times per day on this name. What a loser. Blocked!

0 · Reply

essiepaul Jul. 19 at 9:38 AM

$NVCT dam stock has missed entire bull move in market over the last 3 years. Except for a couple of trade-able moves you would have been much better off in a CD or an S&P 500 index fund

2 · Reply

Market Cap	162.56M
Revenue (ttm)	0.00
Net Income (ttm)	-19.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	152,600
Avg Vol	173,030
Day's Range	N/A - N/A
Shares Out	20.89M
Stochastic %K	29%
Beta	-0.25
Analysts	Strong Sell
Price Target	$19.25